Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma

Stephen C. Mack(Baylor College of Medicine), Irtisha Singh(Baylor College of Medicine), Xiuxing Wang(University of California San Diego), Rachel Hirsch(Baylor College of Medicine), Quilian Wu(University of California San Diego), Rosie Villagomez(Baylor College of Medicine), Jean Bernatchez(University of California San Diego), Zhe Zhu(University of California San Diego), Ryan C. Gimple(University of California San Diego), Leo J.Y. Kim(University of California San Diego), Andrew R. Morton(Case Western Reserve University), Sisi Lai(Case Western Reserve University), Zhixin Qiu(University of California San Diego), Briana C. Prager(University of California San Diego), Kelsey C. Bertrand(Baylor College of Medicine), Clarence K. Mah(University of California San Diego Medical Center), Wenchao Zhou(Cleveland Clinic Lerner College of Medicine), Christine Lee(Cleveland Clinic Lerner College of Medicine), Gene H. Barnett(Cleveland Clinic), Michael A. Vogelbaum(Cleveland Clinic), Andrew E. Sloan(University Hospitals Seidman Cancer Center), Lukas Chávez(University of California San Diego Medical Center), Shideng Bao(Cleveland Clinic Lerner College of Medicine), Peter C. Scacheri(Case Western Reserve University), Jair L. Siqueira-Neto(University of California San Diego), Charles Y. Lin(Baylor College of Medicine), Jeremy N. Rich(University of California San Diego)
The Journal of Experimental Medicine
April 4, 2019
Cited by 141

Abstract

Glioblastoma is an incurable brain cancer characterized by high genetic and pathological heterogeneity. Here, we mapped active chromatin landscapes with gene expression, whole exomes, copy number profiles, and DNA methylomes across 44 patient-derived glioblastoma stem cells (GSCs), 50 primary tumors, and 10 neural stem cells (NSCs) to identify essential super-enhancer (SE)-associated genes and the core transcription factors that establish SEs and maintain GSC identity. GSCs segregate into two groups dominated by distinct enhancer profiles and unique developmental core transcription factor regulatory programs. Group-specific transcription factors enforce GSC identity; they exhibit higher activity in glioblastomas versus NSCs, are associated with poor clinical outcomes, and are required for glioblastoma growth in vivo. Although transcription factors are commonly considered undruggable, group-specific enhancer regulation of the MAPK/ERK pathway predicts sensitivity to MEK inhibition. These data demonstrate that transcriptional identity can be leveraged to identify novel dependencies and therapeutic approaches.


Related Papers

No related papers found

Powered by citation graph analysis